Latest Woolsey Pharmaceuticals News & Updates

See the latest news and media coverage for Woolsey Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Woolsey Pharmaceuticals

Neurodegenerative disease treatment developer

woolseypharma.com

Last updated

Latest news about Woolsey Pharmaceuticals

Company announcements

  • Woolsey Pharmaceuticals

    Woolsey Pharmaceuticals completes Series B extension

    Funds advance BRAVYL ALS program. Completed high-dose enrollment; NfL decreased 15%; TDP-43 pathology reduced. Data expected June 2025.

  • Woolsey Pharmaceuticals

    Woolsey Pharmaceuticals secures U.S. patent claims for BRAVYL in ALS

    USPTO grants claims covering fasudil treatment of ALS and NfL reduction. It adds to existing patents on formulations and sporadic ALS.

  • Woolsey Pharmaceuticals

    Woolsey reveals BRAVYL reduces TDP-43 spread in ALS patients

    Lab findings show 60% reduction in aggregation and cytoplasmic redistribution after 6 months treatment. Presented at ALS/MND Symposium.

  • Woolsey Pharmaceuticals

    Woolsey Pharmaceuticals completes patient recruitment for high-dose ALS study cohort

    Recruitment finished for 300 mg/day cohort (n=31) in REAL study of BRAVYL® after promising results at 180 mg/day, including 15% NfL decrease. Results expected mid-2025.

Unlock all announcements with a

Media coverage

Be the first to know. to get notified the second Woolsey Pharmaceuticals hits the news.

Never miss news about Woolsey Pharmaceuticals

Track Woolsey Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.